Stock code:3164

GenMont Biotech Inc.

Annual Shareholders Meeting 2026

Meeting Handbook

Meeting Type: physical meeting
Meeting Date: June 8, 2026
Meeting Location: No. 99, Yong’ an 1st St., Yongkang Dist., Tainan City, Taiwan (Queena Plaza Hotel)

Table of Contents

1. Meeting Procedures 1

2. Meeting Agenda 2

(1) Report Items 2

(2) Ratification Items 2

(3) Matters for Discussion: 3

(4) Election Items: 3

(5) Other Discussion Items: 3

(6)Extemporary Motion 4

(7) Adjournment 4

3. Attachment 5

Attachment 1:2025 Business Report 5

Attachment 2:Audit Committee Review Report 9

Attachment 3:Execution status of the Company's share repurchase 10

Attachment 4:Independent Auditors Report and 2025 Financial Statements 11

Attachment 5:2025 Earnings Distribution Table 31

Attachment 6:Comparison Table of Amendments to Rules of Procedure for Shareholders Meetings 32

Attachment 7:List of Director Candidates 35

Attachment 8:Concurrent Positions of Director Candidates 38

4. Appendix 39

Appendix 1:Article of Incorporation 39

Appendix 2:Rules of Procedure for Shareholders Meetings (Before Amendment) 45

Appendix 3: Rules for Director Elections 50

Appendix 4: Current Shareholding of Directors 52

Appendix 5: The shareholder proposal 53

1. Meeting Procedures

I. Call the Meeting to Order
II. Chairman’s Remarks
III. Report Items
IV. Ratification Items
V. Matters for Discussion:
VI. Election Items
VII. Other Discussion Items
VIII. Extemporary Motions
IX. Adjournment

2. Meeting Agenda

Meeting Time: June 8, 2026 (Monday), 10:15 a.m.

Location: No. 99, Yong'An 1st St., Yongkang Dist., Tainan City, Taiwan (Queena Plaza Hotel).

(1) Report Items

I. 2025 Business Report.

Description: 2025 Business Report, please refer to Attachment 1 page 5~8.

II. Audit Committee's Review report on the 2025 Financial Statements.

Description: Audit Committee's Review report, please refer to Attachment 2 page 9.

III. Status of the employees' and directors' remuneration of 2025.

Description:

(I) Distribution of employees' and directors' remuneration is based on the resolution by the Board of Directors on March 9, 2025.

(II) The 2025 remuneration to directors and employees is NT $2,044,580 and NT $4,089,160 respectively in cash.

(III) Among the total employees' remuneration, the amount allocated to non-managerial employees is NT$3,168,567, representing 77.49% of the total allocation.

IV. The Report of dividend Distribution for 2026.

Description:

(I) The Company's Articles of Incorporation authorize the Board of Directors to resolve the distribution of cash dividends of NT$0.8 per share (i.e., NT$0.6 per share from earnings and NT$0.2 per share from capital surplus).

(II) The Company authorized the Board of Directors to set cash dividends Ex-dividend base date, allotment date and other relevant matters. While allocating cash dividends to shareholders, the total amount should round to the nearest whole number. The cash dividends less than one dollar should transfer to other company income.

(III) On March 9, 2026, the Company's Board of Directors resolved to set April 14, 2026, as the ex-dividend record date, with the distribution completed on May 8, 2026.

V. Resolution and execution status of the Company's share repurchase

Description: Please refer to Attachment 3 page 10

(2) Ratification Items

I. The Company's 2025 Financial Statements (Proposed by the Board of Directors)

Description:

(I) The Company's 2025 Business Report and Financial Statements were completed. The Financial Statements were audited by independent auditors of KPMG. Also, the

Business Report has been approved by the Audit Committee of the Company.

(II) The business report please refer to Attachment 1 p.5-p.8. Consolidated financial statements please refer to Attachment 4 p.11-p.20. Parent-company only financial statements please refer to Attachment 4 p.21-p.30.

Resolution:

II. The 2025 Earnings Distribution Proposal (Proposed by the Board of Directors)

Description:

(I) The 2025 Earnings Distribution proposal was resolved by the Board of Directors. The 2025 Earnings Distribution Table please refer to page 31 of this handbook (Attachment 5).

Resolution:

(3) Matters for Discussion:

I. Amendment to the Company's "Rules of Procedure for Shareholders Meetings" (Proposed by the Board of Directors)

Description:

(I) The Company proposes to amend certain articles within the "Rules of Procedure for Shareholders Meetings."

(II) For the comparison table of the amended articles, please refer to Attachment 6 page 32 to 34.

Resolution:

(4) Election Items:

Proposal: Election of the 11th Board of Directors (Proposed by the Board of Directors)

Description:

1. The Company's Board of Directors has its term until June 29, 2026. As the term is reaching expiration, the election of the new Board of Directors should be scheduled to take place at the Annual Shareholders Meeting. The total number of directors is nine, within which four independent directors should be included. The new Board of Directors will be inaugurated with a tenure from June 30, 2026 to June 29, 2029.
2. According to the Article 192-1 of Company Act, the candidate's nomination shall be subject to the law. As of the deadline of nomination, no nominee is submitted by the shareholders except for the 9 candidates nominated by the Board of Directors. The enlisted director nominees have been audited and approved by the Board. Please refer to the list of candidates on page 35-37 of this handbook (Attachment 7).

Election results:

(5) Other Discussion Items:

Proposal: Release of restriction on competitive activities of new directors (Proposed by the

Board of Directors)

Description:

1. According to the Article 209 of Company Act, “A director who does anything for himself or on behalf of another person that is within the scope of the Company's business, shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.”
2. For the needs of the Company's business, the new directors elected at the meeting may concurrently act as directors of other companies with similar business as the Company. Please refer to page 38 of this handbook (Attachment 8).
3. The Company proposes the release of restrictions on competitive activities on the new directors.

Resolution:

(6)Extemporary Motion

(7) Adjournment

3. Attachment

Attachment 1:2025 Business Report

GenMont Biotech Inc.

2025 Business Report

Dear Shareholders,

On behalf of GenMont Biotech Inc. (the "Company"), I would like to express our sincere appreciation for your continued support and encouragement over the past year. In 2025, the global economic environment remained complex and volatile. Geopolitical tensions gave rise to ongoing regional conflicts, while disruptions stemming from U.S. tariff policies in the first half of the year led to significant exchange rate fluctuations. Persistent inflationary pressures further weighed on the market and adversely impacted the Company's profitability. In the second half of the year, the Company responded by diversifying its business operations and actively expanding both domestic and international markets through innovative products and raw materials. As a result, the Company recorded annual revenue of NT$354 million, representing a modest increase compared to the previous year, as we continued striving to deliver value in return for our shareholders' long-standing support. The following is a brief overview of the Company's operating performance over the past year:

1. 2025 Corporate earnings and results

(1)Execution results of business plan:

The Company has completed its main products in 2025 and continue to launch new products with many patents issued (203 patent certificates were obtained by the end of 2025 from Taiwan, mainland China, the United States, the United Kingdom, France, Germany, Australia, Japan, Italy, etc.) In 2025, it achieved approximately 3% growth in performance compared to 2024, primarily driven by increased sales in overseas markets. Looking ahead to 2026, the Company plans to further strengthen marketing efforts both domestically and internationally, and actively participate in global trade shows to expand the international sales of functional ingredients. The Company remains committed to enhancing and advancing its core technologies in production processes and R&D. At the same time, it continues to foster industry-academia collaboration, aiming to achieve even stronger operational performance.

(2) Budget execution:

Unit: $ Thousand

Item/Year	2025 Budge	Audited by accountants	
		2025 Amount	Completion Rate (%)
Revenue	371,700	354,544	95.38
Cost of Revenue	118,944	110,517	92.92
Gross Profit	252,756	244,027	96.55
Operation Expenses	148,295	129,045	87.02
Operation Income	104,461	114,982	110.07
Nonoperating income(expense)	(20,680)	(42,086)	(3.51)
Pre-Tax Income	83,781	72,896	87.01
Net-Income	-	57,198	-

Note: The above financial data is based on the parent company only financial statements.

(3) Financial balance and Return on investment analysis:

Unit: NT$ Thousand

Item/Year			2024	2025
Financial balance	Revenue		345,164	354,544
	Gross Profit		234,549	244,027
	Pre-Tax Income /Loss		74,219	72,896
Return on investment analysis	Return On Equity (%)		4.29	4.26
	Ratio to capital (%)	Operation income to capital	11.78	13.37
		Per-tax income to capital	8.58	8.48
	Earnings per share (NT$)		0.66	0.66

(4) Research Development:

Unit:NT$ Thousand

Year	RD expense	Ratio to Revenue %	Main Results
2021	25,524	5.96	•Continually proceed search, purification and storage of lactic acid bacteria •Continually proceed filtering and functional verification of functional lactic acid bacteria •Research and Development of functional lactic acid bacteria •Build the culture technology of high density fermentation •Development and certification of the health food •Initiate the cooperation with academic institutions • Published numerous important articles in foreign journals •Continually apply for the domestic and overseas patents of functional lactic acid bacteria • Clinical trials with major domestic hospitals. • Develop new products to meet market demand.
2022	25,363	6.88	
2023	26,657	8.61	
2024	26,310	7.62	
2025	24,670	6.96	

2．2026 Business Plan

(1) Management policy: 2025 Core Strategy of the Company

I. Expansion of international markets: Disclosure the R&D results of inventive technology and expand the international markets.

II. Marketing policy: Proactively create the OEM and raw-material markets except for the current marketing channels.

III. Innovation and R&D dominated: Develop new markets with innovative thoughts instead of conventional ones and build the new sales markets and new product applications with the modern concept on R&D.

IV. Build up the comprehensive food-safety management system in accordance with the law related the food safety. Conduct relative assessment yearly from the upstream raw-material inputs to the downstream production, storage and transportation. Adjust and enhance the quality and ability of management.

V. Optimize the organizational structure, elevate the hardware devices, advance fermentation technology, and lower production costs.

VI. Factory starts mass production in China. Relevant points will be announced in accordance with the law.

(2) Critical policy of production and marketing:

I. Production policy:

(I)Follow the progress of product R&D and consecutively optimize the manufacturing process and fermentation capacity.
(II)Assess periodically the production and marketing to reduce the sluggish raw materials.
(III)Optimize the plan of production line and strengthen the training of employees

II. Marketing policy:
(I) Continually develop the international markets with innovative-effect raw materials.
(II)Expand the Taiwan and overseas markets by the creative products which meet the real needs of consumers.
(III)Emphasize on the customer development and service. Develop new products based on the needs of customers. Create the market demand and added value for customers.

III. Research and Development policy:
(I)Rapidly develop the new strain on the basis of the market trend.
(II)Continually proceed the research and development of the fundament, production process, and preparation, along with the technology innovation, in order to create the need of the market.
(III)Introduce the latest R&D technology and equipment, and R&D talents, in order to considerably elevate the capability of R&D.
(IV)Cooperate with teaching hospitals, academic and research institutions to advance the capability of R&D.
(V)Implement the plans of various health-food certification and the clinical human trials
(VI)Introduce adequately R&D talents with potentiality and strengthen the training of R&D employees

IV. Quality policy:
(I)Prevent the business reputation of suppliers from being damaged again by the food-safety events as a result of the loose control of governments. Adopt stricter quality control standards than those required by government regulations. Apply relevant laws of the developed countries such as the US and European countries on the food safety management with respect to the parts not regulated by the governments.
(II)Use the legal raw materials, trace the origins, and register to build the product traceability
(III)Cyclically assess the skills of quality control and eliminate the blind spot of failed assessment, inefficiency, and the safety concern.

V. The policy of workplace safety and environmental protection:
(I)Strengthen workplace safe management system and organization. Employ the professional personnels to enhance the protection of workplace safety.
(II)Periodically inspect every place and equipment, especially the power system, in order to lessen the check neglect of blind corner space.
(III)Regularly conduct the fire drill to make employees familiar with the methods of disaster prevention, escape and disaster relief.
(IV)Energy conservation of the Electricity, water and fuel
(V)Using the water from solar preheating process, implement energy conservation and carbon reduction
(VI)Recycling by the RO to filter out water
(VII)Carry out the waste sorting and recycling
(VIII)Actively promote and implement the spirit of sustainable development.

3、 Future business development

1. By leveraging proprietary technologies and exclusive raw materials, integrating customized OEM services, and enhancing global visibility through active participation in international conferences and exhibitions, the Company aims to strengthen its R&D and innovation advantages and progressively expand into overseas markets.
2. Shape the excellent and innovation images of the Company. Build the brand value of GenMont Biotech Inc.

4、The impact of the competitive environment, legal limits and the entire management conditions

(1) Probiotics markets is growing year by year. Chinese competitive companies are rising rapidly and the competition of international markets become increasingly fierce.

(2) Given Taiwan's limited market size, weakening consumer demand in recent years, and the proliferation of imitative products, the Company will pursue product differentiation while strengthening the integration of its online sales platforms and expanding its physical distribution network to increase product penetration and enhance its competitiveness.

(3) The capability of international R&D is enhancing remarkably, whereas that of Taiwan is lower. We need to reinforce the ability of R&D.

(4) In response to the intensifying geopolitical tensions and an increasingly unpredictable global landscape, the Company is expanding its presence in Europe, the United States, and the Southeast Asia to mitigate the risks associated with overconcentration in a single market.

Chairman: Chen Ken-te

Manager: Chen Yu Chin

Accounting Manager: Huang Chao Tang

Attachment 2:Audit Committee Review Report

Audit Committee Review Report

The Board of Directors has prepared the Company's Business Report, Financial Statements, and Earnings Distribution Table for 2025. KPMG was retained to audit the Company's Financial Statements and the accountants Mr. Su, Yan-Da and Mr. Hsu, Zhen-Long have issued an audited the report relating to the individual and consolidated Financial Statements.

The above Financial Statements have been reviewed and determined to be correct and accurate by the Audit Committee of the Company. In accordance with Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, I hereby submit this report.

2026 Annual Shareholders' Meeting

GenMont Biotech Inc.

Convener of the Audit Committee: Huang Tse-jen

March 9th, 2026

Attachment 3:Execution status of the Company’s share repurchase

Execution Status of the Company’s Share Repurchase (Completed)

December 31, 2025

Repurchase tranche	First
Purpose of repurchase	To maintain the Company’s credit standing and protect shareholders’ interests
Repurchase period	2025/05/29 ~ 2025/07/28
Repurchase price range	NT$14.32 ~ NT$30.74
Type and number of shares repurchased	501,000 ordinary shares
Total amount of shares repurchased	NT$10,334,384
Percentage of shares repurchased to planned repurchase quantity (%)	50.1%
Number of shares cancelled and transferred	0 shares
Cumulative number of treasury shares held	0 shares
Percentage of treasury shares held to total issued shares (%)	0%

Attachment 4:Independent Auditors Report and 2025 Financial Statements

Independent Auditors' Report

To the Board of Directors of GenMont Biotech Inc.

Audit opinion

We have audited the consolidated balance sheets of GenMont Biotech Inc. and its subsidiaries (hereinafter referred to as "GenMont Group") as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and the notes to consolidated financial statements (including a summary on significant accounting policies).

In our opinion, the aforementioned consolidated financial statements present fairly, in all material respects, the consolidated financial status of GenMont Group as of December 31, 2025 and 2024, and its consolidated financial performance and cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for audit opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and auditing standards. Our responsibilities under those standards are further described in the auditors' responsibilities for the audit of the consolidated financial statements section of our report. We are independent of GenMont Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China ("the Norm"), and we have fulfilled our other responsibilities in accordance with the Norm. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are ones that were of most significance in our audit of the consolidated financial statements of GenMont Group for the year ended December 31, 2025 based on our professional judgment. These matters have been covered during the audit of the overall consolidated financial statements and in forming the audit opinion. We will not express a separate opinion on these matters. Key audit matters to be communicated on the independent auditors' report are stated as follows:

1. Assessment of inventory obsolescence loss

   Please refer to Note 4(8) of the accompanying consolidated financial statements for accounting policies concerning inventory, Note 5(1) for accounting estimates and assumption uncertainty concerning inventory, and Note 6(5) for disclosures pertaining to inventory write-downs.

   Description of key audit matter:

   The primary inventory of GenMont Group consists of various probiotic supplements. Market demand and other factors may cause existing products to become outdated or misaligned with market needs, leading to inventory obsolescence. This increases the risk that inventory costs may exceed the net realizable value. As a result, the evaluation of inventory obsolescence loss is one of the key audit matters in our audit of GenMont Group's consolidated financial statements.

Audit procedures:

Our key audit procedures for the aforementioned key audit matter included:

- Gaining an understanding of management's inventory obsolescence valuation policy and comparing it to historical obsolescence data to assess the accuracy of past estimates.
- Obtaining the inventory aging report, selecting samples, and tracing them to inventory movement records to verify the accuracy of aging calculations.
- Recalculating the inventory obsolescence allowances based on applicable obsolescence rates for different aging brackets.
- Assessing the adequacy of GenMont Group's disclosures regarding inventory allowances.

2. Assessment on impairment of long-term non-financial assets

Please refer to Note 4(12) of the accompanying consolidated financial statements for accounting policies concerning the impairment assessment of long-term non-financial assets of GenMont Biotech (China) Co., Ltd. (GenMont (China)), Note 5(2) for relevant accounting estimates and assumption uncertainty, and Note 6(7) and (8) for details on the impairment assessment of long-term non-financial assets.

Description of key audit matter:

The industry in which GenMont (China) operates is susceptible to changes in market conditions and the recoverable amount for impairment assessment of long-term non-financial assets is based on external experts' assessments. As the assessment outcome would directly affect the carrying amount of long-term non-financial assets, the assessment on impairment of long-term non-financial assets was considered one of the key audit matters in our audit of GenMont Group's consolidated financial statements.

Audit procedures:

Our key audit procedures for the aforementioned key audit matter included:

- Evaluating the professional competence, qualifications, and independence of the external valuation expert engaged by the Company.
- Engaging a third-party valuation expert to assist in reviewing and assessing the appropriateness of the valuation methodology selected and the reasonableness of the underlying assumptions in the valuation report.
- Assessing the adequacy of GenMont Group's disclosures concerning the assessment on impairment of long-term non-financial assets.

Other Matters

GenMont Biotech Inc. has prepared the parent company only financial statements for the years ended December 31, 2025 and 2024, which we had audited and issued an unqualified opinion.

Responsibilities of management and those charged with governance for the consolidated financial statements

The responsibilities of management are to prepare the consolidated financial statements with fair presentation in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRSs, IASs, IFRICs, and SICs endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and maintain necessary internal controls associated with the preparation in order to ensure the financial statements are free from material misstatement arising from fraud or error.

In preparing the consolidated financial statements, management is also responsible for assessing the ability of GenMont Group in continuing as a going concern, disclosing associated matters and adopting the going concern basis of accounting unless the management intends to liquidate GenMont Group or cease the operations, or has no realistic alternative but to do so.

Those charged with governance of GenMont Group (including the Audit Committee) are responsible for supervising the financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance on whether the consolidated financial statements as a whole are free from material misstatement arising from fraud or error, and to issue an independent auditors' report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error. If those amounts of misstatements, either individually or in the aggregate, could reasonably be expected to influence the economic decisions of financial statement users, they are considered material.

We have exercised professional judgment and professional skepticism when carrying out auditing work according to the auditing standards. We also perform the following tasks:

1. Identify and assess the risks of material misstatement arising from fraud or error within the consolidated financial statements; design and execute appropriate counter-measures in response to those risks, and obtain sufficient and appropriate audit evidence to provide a basis for our opinion. Fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Therefore, the risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error.
2. Understand internal controls relevant to the audit in order to design appropriate audit procedures under the circumstances, but not for the purpose of expressing an opinion on the effectiveness of GenMont Group's internal control.
3. Evaluate the appropriateness of accounting policies adopted and the reasonableness of accounting estimates and relevant disclosures made by management.
4. Based on the audit evidence obtained, we conclude on the appropriateness of management's use of the going concern basis of accounting and whether a material uncertainty exists for events or conditions that may cast significant doubts on GenMont Group's ability to continue as a going concern. If we are of the opinion that a material uncertainty exists, we shall remind users of the consolidated financial statements to pay attention to relevant disclosures in the notes to those statements within our audit report. If such disclosures are inadequate, we need to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may result in GenMont Group ceasing to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements (including relevant notes), and whether the consolidated financial statements adequately represent the underlying transactions and events.
6. Obtain sufficient and appropriate audit evidence concerning the financial information of entities within GenMont Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and execution of the audit and the preparation of an audit opinion on GenMont Group.

Matters communicated between us and the governance bodies include the planned scope and timing of the audit, and significant audit findings (including any significant deficiencies in internal control identified during the audit).

We also provide governance bodies with a declaration that we have complied with the Norm regarding independence, and to communicate with them all relationships and other matters that may possibly be deemed to impair our independence (including relevant preventive measures).

From the matters communicated with governance bodies, we determine the key audit matters within the audit of GenMont Group's consolidated financial statements for the year ended December 31, 2025. We have clearly indicated such matters in the independent auditors' report, unless legal regulations prohibit the public disclosure of specific items, or in extremely rare cases, where we decided not to communicate over specific items in the independent auditors' report for it could be reasonably anticipated that the negative effects of such disclosure would be greater than the public interest it brings forth.

KPMG Taiwan

March 9, 2026

GENMONT BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	December 31, 2025		December 31, 2024	
ASSETS	**Amount**	**%**	**Amount**	**%**
CURRENT ASSETS				
Cash and cash equivalents (Note 6(1))	$ 103,732	6	110,513	6
Financial assets at amortized cost - current (Note 6(3))	261,624	16	248,130	15
Notes and accounts receivable, net (Note 6(4) & (17))	46,156	3	31,599	2
Other receivables	738	-	1,730	-
Inventories (Note 6(5))	70,386	4	77,668	5
Prepayments and other current assets	5,233	-	4,920	-
Other financial assets - current (Note 8)	67,440	4	67,170	4
Total current assets	555,309	33	541,730	32
NON-CURRENT ASSETS				
Financial assets at fair value through profit or loss - non-current (Note 6(2))	-	-	6,090	-
Property, plant and equipment (Note 6(7))	914,628	55	972,217	57
Right-of-use assets (Note 6(8))	61,662	4	64,619	4
Intangible assets	2,009	-	2,155	-
Deferred income tax assets (Note 6(14))	51,838	3	42,041	2
Net defined benefit assets - non-current (Note 6(13))	9,290	1	8,296	1
Other financial assets - non-current (Note 8)	67,440	4	67,170	4
Other non-current assets	2,907	-	4,424	-
Total non-current assets	1,109,774	67	1,167,012	68
TOTAL	**$ 1,665,083**	**100**	**1,708,742**	**100**

(The accompanying notes are an integral part of the consolidated financial statements.)

(Continued)

GENMONT BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS - (Continued)
DECEMBER 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	December 31, 2025		December 31, 2024	
LIABILITIES AND EQUITY	**Amount**	**%**	**Amount**	**%**
CURRENT LIABILITIES				
Short-term borrowings (Notes 6(9) & 8)	$ 23,501	2	20,478	1
Contract liabilities - current (Note 6(17))	22,039	1	40,049	2
Notes and accounts payable	8,141	-	6,304	-
Other payables	42,717	3	43,316	3
Current income tax liabilities	22,735	2	12,187	1
Lease liabilities - current (Note 6(12))	1,759	-	2,404	-
Refund liabilities - current (Note 6(11) & (17))	1,577	-	3,165	-
Current portion of long-term borrowings (Notes 6(10) & 8)	7,310	-	12,242	1
Total current liabilities	129,779	8	140,145	8
NON-CURRENT LIABILITIES				
Long-term borrowings (Notes 6(10) & 8)	44,896	3	49,227	3
Deferred income tax liabilities (Note 6(14))	5,519	-	3,114	-
Lease liabilities - non-current (Note 6(12))	32,841	2	34,261	2
Guarantee deposits received	2,318	-	2,318	-
Total non-current liabilities	85,574	5	88,920	5
Total liabilities	215,353	13	229,065	13
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 6(14) & (15))				
Ordinary shares	860,104	52	865,114	50
Capital surplus	351,774	21	353,744	21
Retained earnings	113,340	7	128,017	8
Other equity	5,663	-	4,904	-
Total equity attributable to owners of the Company	1,330,881	80	1,351,779	79
NON-CONTROLLING INTERESTS (Note 6(6))	118,849	7	127,898	8
Total equity	1,449,730	87	1,479,677	87
TOTAL	**$ 1,665,083**	**100**	**1,708,742**	**100**

(The accompanying notes are an integral part of the consolidated financial statements.)

(Concluded)

GENMONT BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	2025		2024	
	Amount	%	Amount	%
Operating revenue (Note 6(17)	$ 401,229	100	385,373	100
Operating costs (Notes 6(5), (13) & (18) & 12)	149,595	37	147,194	38
Gross profit	251,634	63	238,179	62
Operating expenses (Notes 6(4), (12), (13) & (18), 7 & 12)				
Selling and marketing expenses	44,638	11	45,991	12
General and administrative expenses	103,185	26	106,798	27
Research and development expenses	45,335	11	45,272	12
Expected credit loss (gain)	725	-	(516)	-
Total operating expenses	193,883	48	197,545	51
Profit from operations	57,751	15	40,634	11
Non-operating income and expenses (Note 6(12) & (19))				
Interest income	7,055	2	11,269	3
Other gains and losses	2,789	1	16,534	4
Finance costs	(3,915)	(1)	(3,718)	(1)
Total non-operating income and expenses	5,929	2	24,085	6
Profit before income tax	63,680	17	64,719	17
Less: Income tax expense (Note 6(14))	15,698	4	16,968	5
Net profit	47,982	13	47,751	12
Other comprehensive income (loss) (Note 6(14) & (15))				
Items that will not be reclassified subsequently to profit or loss				
Remeasurement of defined benefit plan	860	-	871	-
Less: Income tax related to items that will not be reclassified subsequently	172	-	174	-
	688	-	697	-
Items that may be reclassified subsequently to profit or loss				
Exchange differences on translation of foreign operations	1,116	-	30,558	8
Less: Income tax related to items that may be reclassified subsequently	190	-	5,195	1
	926	-	25,363	7
Other comprehensive income (loss), net of income tax	1,614	-	26,060	7
Total comprehensive income	**$ 49,596**	**13**	**73,811**	**19**
Net profit (loss) attributable to:				
Owners of the Company	$ 57,198	15	57,251	15
Non-controlling interests	(9,216)	(2)	(9,500)	(3)
	$ 47,982	**13**	**47,751**	**12**
Total comprehensive income attributable to:				
Owners of the Company	$ 58,645	15	78,728	20
Non-controlling interests	(9,049)	(2)	(4,917)	(1)
	$ 49,596	**13**	**73,811**	**19**
Earnings (loss) per share (NT$) (Note 6(16))				
Basic	**$**	**0.66**		**0.66**
Diluted	**$**	**0.66**		**0.66**

(The accompanying notes are an integral part of the consolidated financial statements.)

GENMONT BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company										
			Retained Earnings				Other Equity				
	Ordinary Shares	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Total	Exchange Differences on Translation of Foreign Operations	Treasury Shares	Total Equity Attributable to Owners of the Company	Non-Controlling Interests	Total Equity
Balance as of January 1, 2024	$ 865,114	377,102	46,479	5,579	37,909	89,967	(15,876)	-	1,316,307	132,815	1,449,122
Net income (loss) for the period	-	-	-	-	57,251	57,251	-	-	57,251	(9,500)	47,751
Other comprehensive income (loss) for the period	-	-	-	-	697	697	20,780	-	21,477	4,583	26,060
Total comprehensive income for the period	-	-	-	-	57,948	57,948	20,780	-	78,728	(4,917)	73,811
Appropriation and distribution of earnings											
Appropriation of legal reserve	-	-	3,292	-	(3,292)	-	-	-	-	-	-
Reversal of special reserve	-	-	-	10,297	(10,297)	-	-	-	-	-	-
Cash dividends for ordinary shares	-	-	-	-	(19,898)	(19,898)	-	-	(19,898)	-	(19,898)
Cash dividends from capital surplus	-	(23,358)	-	-	-	-	-	-	(23,358)	-	(23,358)
Balance as of December 31, 2024	**865,114**	**353,744**	**49,771**	**15,876**	**62,370**	**128,017**	**4,904**	**-**	**1,351,779**	**127,898**	**1,479,677**
Net income (loss) for the period	-	-	-	-	57,198	57,198	-	-	57,198	(9,216)	47,982
Other comprehensive income (loss) for the period	-	-	-	-	688	688	759	-	1,447	167	1,614
Total comprehensive income for the period	-	-	-	-	57,886	57,886	759	-	58,645	(9,049)	49,596
Appropriation and distribution of earnings											
Appropriation of legal reserve	-	-	5,795	-	(5,795)	-	-	-	-	-	-
Reversal of special reserve	-	-	-	(15,876)	15,876	-	-	-	-	-	-
Cash dividends for ordinary shares	-	-	-	-	(69,209)	(69,209)	-	-	(69,209)	-	(69,209)
Repurchase of treasury shares	-	-	-	-	-	-	-	(10,334)	(10,334)	-	(10,334)
Cancellation of treasury shares	(5,010)	(1,970)	-	-	(3,354)	(3,354)	-	10,334	-	-	-
Balance as of December 31, 2025	**$ 860,104**	**351,774**	**55,566**	**-**	**57,774**	**113,340**	**5,663**	**-**	**1,330,881**	**118,849**	**1,449,730**

(The accompanying notes are an integral part of the consolidated financial statements.)

GENMONT BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
Cash flows from operating activities:		
Profit before income tax	$ 63,680	64,719
Adjustments:		
Non-cash income and expense items		
Depreciation	66,564	71,199
Amortization	391	393
Expected credit loss (gain)	725	(516)
Net (gain) loss on financial assets and liabilities at fair value through profit or loss	(4,016)	1,230
Interest expense	3,915	3,718
Interest income	(7,055)	(11,269)
Dividend income	(330)	(330)
Loss on disposal of property, plant and equipment	1	18
Unrealized gain on foreign currency exchange	(15,360)	(5,832)
Total non-cash income and expense items	44,835	58,611
Changes in operating assets and liabilities:		
Net changes in operating assets:		
(Increase) decrease in notes and accounts receivable	(15,332)	7,182
Decrease in other receivables	647	33
Decrease in inventories	7,066	10,096
(Increase) decrease in prepayments and other current assets	(239)	4,096
Increase in net defined benefit assets - non-current	-	(88)
Total net changes in operating assets	(7,858)	21,319
Net changes in operating liabilities:		
(Decrease) increase in contract liabilities	(17,969)	6,074
Increase (decrease) in notes and accounts payable	1,822	(1,548)
(Decrease) increase in other payables	(763)	3,545
Decrease in refund liabilities	(1,722)	(6,767)
Total net changes in operating liabilities	(18,632)	1,304
Total net changes in operating assets and liabilities	(26,490)	22,623
Total adjustments	18,345	81,234
Cash generated from operations	82,025	145,953
Interest received	8,061	11,297
Dividend received	330	330
Interest paid	(3,915)	(3,718)
Income tax paid	(12,904)	(29,916)
Net cash generated by operating activities	73,597	123,946

(The accompanying notes are an integral part of the consolidated financial statements.)

(Continued)

GENMONT BIOTECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS - (Continued)
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
Cash flows from investing activities:		
Acquisition of financial assets at amortized cost	$ (609,616)	(682,900)
Disposal of financial assets at amortized cost	603,190	710,481
Disposal of financial assets at fair value through profit or loss	10,106	-
Acquisition of property, plant and equipment	(3,407)	(44,054)
Acquisition of intangible assets	(247)	(221)
Decrease (increase) in other financial assets	6,209	(67,337)
Decrease in other non-current assets	1,464	1,608
Net cash generated by (used in) investing activities	7,699	(82,423)
Cash flows from financing activities:		
Increase in short-term borrowings	45,841	42,166
Decrease in short-term borrowings	(43,007)	(21,798)
Proceeds from long-term borrowings	-	43,649
Repayments of long-term borrowings	(9,166)	(5,512)
Decrease in guarantee deposits received	-	(50)
Repayment of lease principal	(2,762)	(2,645)
Cash dividends from capital surplus	-	(23,358)
Distribution of cash dividends	(69,209)	(19,898)
Cost of treasury shares repurchased	(10,334)	-
Net cash (used in) generated by financing activities	(88,637)	12,554
Effect of exchange rate changes on cash and cash equivalents	560	841
Net (decrease) increase in cash and cash equivalents	(6,781)	54,918
Cash and cash equivalents at beginning of period	110,513	55,595
Cash and cash equivalents at end of period	**$ 103,732**	**110,513**

(The accompanying notes are an integral part of the consolidated financial statements.)

(Concluded)

Independent Auditors' Report

To the Board of Directors of GenMont Biotech Inc.

Audit opinion

We have audited the parent company only balance sheets of GenMont Biotech Inc. (hereinafter referred to as the "Company") as of December 31, 2025 and 2024, and the related parent company only statements of comprehensive income, changes in equity and cash flows for the years then ended, and the notes to parent company only financial statements (including a summary on significant accounting policies).

In our opinion, the aforementioned parent company only financial statements present fairly, in all material respects, the financial status of the Company as of December 31, 2025 and 2024, and its financial performance and cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for audit opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and auditing standards. Our responsibilities under those standards are further described in the auditors' responsibilities for the audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China ("the Norm"), and we have fulfilled our other responsibilities in accordance with the Norm. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are ones that were of most significance in our audit of the parent company only financial statements of the Company for the year ended December 31, 2025 based on our professional judgment. These matters have been covered during the audit of the overall parent company only financial statements and in forming the audit opinion. We will not express a separate opinion on these matters. Key audit matters to be communicated on the independent auditors' report are stated as follows:

3. Assessment of inventory obsolescence loss

   Please refer to Note 4(7) of the accompanying parent company only financial statements for accounting policies concerning inventory, Note 5(1) for accounting estimates and assumption uncertainty concerning inventory valuation, and Note 6(5) for disclosures pertaining to inventory write-downs.

   Description of key audit matter:

   The primary inventory of the Company consists of various probiotic supplements. Market demand and other factors may cause existing products to become outdated or misaligned with market needs, leading to inventory obsolescence. This increases the risk that inventory costs may exceed the net realizable value. As a result, the evaluation of inventory obsolescence loss is one of the key audit matters in our audit of the Company's parent company only financial statements.

   Audit procedures:

   Our key audit procedures for the aforementioned key audit matter included:

- Gaining an understanding of management's inventory obsolescence valuation policy and comparing it to historical obsolescence data to assess the accuracy of past estimates.
- Obtaining the inventory aging report, selecting samples, and tracing them to inventory movement records to verify the accuracy of aging calculations.
- Recalculating the inventory obsolescence allowances based on applicable obsolescence rates for different aging brackets.
- Assessing the adequacy of the Company's disclosures regarding inventory allowances.

4. Impairment assessment of long-term non-financial assets of the investee subsidiary

   Please refer to Note 4(12) of the accompanying parent company only financial statements for accounting policies concerning the impairment assessment of long-term non-financial assets of the investee subsidiary, Note 5(2) for relevant accounting estimates and assumption uncertainty, and Note 6(6) for details on the impairment assessment of long-term non-financial assets of the investee subsidiary.

   Description of key audit matter:

   The industry in which the investee subsidiary operates is susceptible to changes in market conditions and the recoverable amount for impairment assessment of long-term non-financial assets of the investee subsidiary is based on external experts' assessments. As the assessment outcome would directly affect the carrying amount of long-term non-financial assets, the impairment assessment of long-term non-financial assets of the investee subsidiary was considered one of the key audit matters in our audit of the Company's parent company only financial statements.

   Audit procedures:

   Our key audit procedures for the aforementioned key audit matter included:

   - Evaluating the professional competence, qualifications, and independence of the external valuation expert engaged by the Company.
   - Engaging a third-party valuation expert to assist in reviewing and assessing the appropriateness of the valuation methodology selected and the reasonableness of the underlying assumptions in the valuation report.
   - Assessing the adequacy of the Company's disclosures concerning the assessment on impairment of long-term non-financial assets.

Responsibilities of management and those charged with governance for the parent company only financial statements

The responsibilities of management are to prepare the parent company only financial statements with fair presentation in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and to maintain necessary internal controls associated with the preparation in order to ensure the financial statements are free from material misstatement arising from fraud or error.

In preparing the parent company only financial statements, management is also responsible for assessing the ability of the Company in continuing as a going concern, disclosing associated matters and adopting the going concern basis of accounting unless the management intends to liquidate the Company or cease the operations, or has no realistic alternative but to do so.

Those charged with governance of the Company (including the Audit Committee) are responsible for supervising the financial reporting process.

Auditors' responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance on whether the parent company only financial statements as a whole are free from material misstatement arising from fraud or error, and to issue an independent auditors' report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error. If those amounts of misstatements, either individually or in the aggregate, could reasonably be expected to influence the economic decisions of financial statement users, they are considered material.

We have exercised professional judgment and professional skepticism when carrying out auditing work according to the auditing standards. We also perform the following tasks:

7. Identify and assess the risks of material misstatement arising from fraud or error within the parent company only financial statements; design and execute appropriate counter-measures in response to those risks, and obtain sufficient and appropriate audit evidence to provide a basis for our opinion. Fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Therefore, the risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error.
8. Understand internal controls relevant to the audit in order to design appropriate audit procedures under the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
9. Evaluate the appropriateness of accounting policies adopted and the reasonableness of accounting estimates and relevant disclosures made by management.
10. Based on the audit evidence obtained, we conclude on the appropriateness of management's use of the going concern basis of accounting and whether a material uncertainty exists for events or conditions that may cast significant doubts on the Company's ability to continue as a going concern. If we are of the opinion that a material uncertainty exists, we shall remind users of the parent company only financial statements to pay attention to relevant disclosures in the notes to those statements within our audit report. If such disclosures are inadequate, we need to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may result in the Company ceasing to continue as a going concern.
11. Evaluate the overall presentation, structure and content of the parent company only financial statements (including relevant notes), and whether the parent company only financial statements adequately represent the underlying transactions and events.
12. Obtain sufficient and appropriate audit evidence concerning the financial information of investees accounted for using the equity method to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision, and execution of the audit and the preparation of an audit opinion on the Company.

Matters communicated between us and the governance bodies include the planned scope and timing of the audit, and significant audit findings (including any significant deficiencies in internal control identified during the audit).

We also provide governance bodies with a declaration that we have complied with the Norm regarding independence, and to communicate with them all relationships and other matters that may possibly be deemed to impair our independence (including relevant preventive measures).

From the matters communicated with governance bodies, we determine the key audit matters within the audit of the Company's parent company only financial statements for the year ended December 31, 2025. We have clearly indicated such matters in the independent auditors' report, unless legal regulations prohibit the public disclosure of specific items, or in extremely rare cases, where we decided not to communicate over specific items in the independent auditors' report for it could be reasonably anticipated that the negative effects of such disclosure would be greater than the public interest it brings forth.

KPMG Taiwan

March 9, 2026

GENMONT BIOTECH INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	December 31, 2025		December 31, 2024	
ASSETS	**Amount**	**%**	**Amount**	**%**
CURRENT ASSETS				
Cash and cash equivalents (Note 6(1))	$ 102,344	7	99,053	7
Financial assets at amortized cost - current (Note 6(3))	261,624	18	248,130	17
Notes and accounts receivable, net (Note 6(4) & (15))	43,729	3	28,230	2
Other receivables	738	-	1,729	-
Other receivables - related parties (Note 7)	20,147	1	18,640	1
Inventories (Note 6(5))	37,427	3	37,948	3
Prepayments and other current assets	2,994	-	3,387	-
Other financial assets - current (Note 8)	67,440	5	67,170	4
Total current assets	536,443	37	504,287	34
NON-CURRENT ASSETS				
Financial assets at fair value through profit or loss - non-current (Note 6(2))	-	-	6,090	-
Investments accounted for using the equity method (Note 6(6))	673,481	46	724,757	49
Property, plant and equipment (Note 6(7))	89,233	6	99,681	7
Right-of-use assets (Note 6(8))	32,040	2	34,414	2
Intangible assets	337	-	236	-
Deferred income tax assets (Note 6(12))	51,838	3	42,041	3
Net defined benefit assets - non-current (Note 6(11))	9,290	1	8,296	1
Other financial assets - non-current (Note 8)	67,440	5	67,170	4
Other non-current assets	2,402	-	3,156	-
Total non-current assets	926,061	63	985,841	66
TOTAL	**$ 1,462,504**	**100**	**1,490,128**	**100**

(The accompanying notes are an integral part of the parent company only financial statements.)

(Continued)

GENMONT BIOTECH INC.
PARENT COMPANY ONLY BALANCE SHEETS - (Continued)
DECEMBER 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	December 31, 2025		December 31, 2024	
LIABILITIES AND EQUITY	**Amount**	**%**	**Amount**	**%**
CURRENT LIABILITIES				
Contract liabilities - current (Note 6(15))	$ 20,982	1	38,337	3
Notes and accounts payable	7,964	1	6,304	-
Other payables	35,928	3	36,259	3
Current income tax liabilities	22,735	2	12,187	1
Lease liabilities - current (Note 6(10))	1,759	-	2,404	-
Refund liabilities - current (Note 6(9) & (15))	1,577	-	3,165	-
Total current liabilities	90,945	7	98,656	7
NON-CURRENT LIABILITIES				
Deferred income tax liabilities (Note 6(12))	5,519	-	3,114	-
Lease liabilities - non-current (Note 6(10))	32,841	2	34,261	2
Guarantee deposits received	2,318	-	2,318	-
Total non-current liabilities	40,678	2	39,693	2
Total liabilities	131,623	9	138,349	9
EQUITY (Note 6(12) & (13))				
Ordinary shares	860,104	59	865,114	58
Capital surplus	351,774	24	353,744	24
Retained earnings	113,340	8	128,017	9
Other equity	5,663	-	4,904	-
Total equity	1,330,881	91	1,351,779	91
TOTAL	**$ 1,462,504**	**100**	**1,490,128**	**100**

(The accompanying notes are an integral part of the parent company only financial statements.)

(Concluded)

GENMONT BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	2025		2024	
	Amount	**%**	**Amount**	**%**
Operating revenue (Note 6(15))	$ 354,544	100	345,164	100
Operating costs (Notes 6(5), (11) & (16) & 12)	110,517	31	110,615	32
Gross profit	244,027	69	234,549	68
Operating expenses (Notes 6(4), (10), (11) & (16), 7 & 12)				
Selling and marketing expenses	44,040	12	45,366	13
General and administrative expenses	59,610	17	61,474	18
Research and development expenses	24,670	7	26,310	7
Expected credit loss (gain)	725	-	(516)	-
Total operating expenses	129,045	36	132,634	38
Profit from operations	114,982	33	101,915	30
Non-operating income and expenses (Note 6(10) & (17))				
Interest income	7,050	2	11,248	3
Other gains and losses	3,986	1	15,800	5
Finance costs	(897)	-	(909)	-
Share of loss of subsidiaries accounted for using the equity method	(52,225)	(15)	(53,835)	(16)
Total non-operating income and expenses	(42,086)	(12)	(27,696)	(8)
Profit before income tax	72,896	21	74,219	22
Less: Income tax expense (Note 6(12))	15,698	4	16,968	5
Net profit	57,198	17	57,251	17
Other comprehensive income (loss) (Note 6(12) & (13))				
Items that will not be reclassified subsequently to profit or loss				
Remeasurement of defined benefit plan	860	-	871	-
Less: Income tax related to items that will not be reclassified subsequently	172	-	174	-
	688	-	697	-
Items that may be reclassified subsequently to profit or loss				
Exchange differences on translation of foreign operations	949	-	25,975	8
Less: Income tax related to items that may be reclassified subsequently	190	-	5,195	2
	759	-	20,780	6
Other comprehensive income (loss), net of income tax	1,447	-	21,477	6
Total comprehensive income	**$ 58,645**	**17**	**78,728**	**23**
Earnings per share (NT$) (Note 6(14))				
Basic	**$**	**0.66**		**0.66**
Diluted	**$**	**0.66**		**0.66**

(The accompanying notes are an integral part of the parent company only financial statements.)

GENMONT BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

			Retained Earnings				Other Equity		
	Ordinary Shares	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Total	Exchange Differences on Translation of Foreign Operations	Treasury Shares	Total Equity
Balance as of January 1, 2024	$ 865,114	377,102	46,479	5,579	37,909	89,967	(15,876)	-	1,316,307
Net income for the period	-	-	-	-	57,251	57,251	-	-	57,251
Other comprehensive income (loss) for the period	-	-	-	-	697	697	20,780	-	21,477
Total comprehensive income for the period	-	-	-	-	57,948	57,948	20,780	-	78,728
Appropriation and distribution of earnings									
Appropriation of legal reserve	-	-	3,292	-	(3,292)	-	-	-	-
Appropriation of special reserve	-	-	-	10,297	(10,297)	-	-	-	-
Cash dividends for ordinary shares	-	-	-	-	(19,898)	(19,898)	-	-	(19,898)
Cash dividends from capital surplus	-	(23,358)	-	-	-	-	-	-	(23,358)
Balance as of December 31, 2024	**865,114**	**353,744**	**49,771**	**15,876**	**62,370**	**128,017**	**4,904**	**-**	**1,351,779**
Net income for the period	-	-	-	-	57,198	57,198	-	-	57,198
Other comprehensive income (loss) for the period	-	-	-	-	688	688	759	-	1,447
Total comprehensive income for the period	-	-	-	-	57,886	57,886	759	-	58,645
Appropriation and distribution of earnings									
Appropriation of legal reserve	-	-	5,795	-	(5,795)	-	-	-	-
Reversal of special reserve	-	-	-	(15,876)	15,876	-	-	-	-
Cash dividends for ordinary shares	-	-	-	-	(69,209)	(69,209)	-	-	(69,209)
Repurchase of treasury shares	-	-	-	-	-	-	-	(10,334)	(10,334)
Cancellation of treasury shares	(5,010)	(1,970)	-	-	(3,354)	(3,354)	-	10,334	-
Balance as of December 31, 2025	**$ 860,104**	**351,774**	**55,566**	**-**	**57,774**	**113,340**	**5,663**	**-**	**1,330,881**

(The accompanying notes are an integral part of the parent company only financial statements.)

GENMONT BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
Cash flows from operating activities:		
Profit before income tax	$ 72,896	74,219
Adjustments:		
Non-cash income and expense items		
Depreciation	16,840	19,901
Amortization	120	103
Expected credit loss (gain)	725	(516)
Net (gain) loss on financial assets at fair value through profit or loss	(4,016)	1,230
Interest expense	897	909
Interest income	(7,050)	(11,248)
Dividend income	(330)	(330)
Share of loss of subsidiaries accounted for using the equity method	52,225	53,835
Loss on disposal of property, plant and equipment	1	-
Unrealized gain on foreign currency exchange	(17,696)	(6,661)
Total non-cash income and expense items	41,716	57,223
Changes in operating assets and liabilities:		
Net changes in operating assets:		
(Increase) decrease in notes and accounts receivable	(15,563)	10,255
(Increase) decrease in other receivables	(15)	34
Decrease in other receivables - related parties	829	742
Decrease in inventories	521	11,486
Decrease (increase) in prepayments and other current assets	393	(812)
Increase in net defined benefit assets - non-current	(134)	(88)
Total net changes in operating assets	(13,969)	21,617
Net changes in operating liabilities:		
(Decrease) increase in contract liabilities	(17,355)	4,360
Increase (decrease) in notes and accounts payable	1,660	(1,548)
(Decrease) increase in other payables	(457)	2,931
Decrease in refund liabilities	(1,588)	(6,767)
Total net changes in operating liabilities	(17,740)	(1,024)
Total net changes in operating assets and liabilities	(31,709)	20,593
Total adjustments	10,007	77,816
Cash generated from operations	82,903	152,035
Interest received	8,056	11,276
Dividend received	330	330
Interest paid	(897)	(909)
Income tax paid	(12,904)	(29,916)
Net cash generated by operating activities	77,488	132,816

(The accompanying notes are an integral part of the parent company only financial statements.)

(Continued)

GENMONT BIOTECH INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS - (Continued)
For the Years Ended December 31, 2025 and 2024
(In Thousands of New Taiwan Dollars)

		2025	2024
Cash flows from investing activities:			
Acquisition of financial assets at amortized cost	$	(609,616)	(682,900)
Disposal of financial assets at amortized cost		603,190	710,481
Proceeds from disposal of financial assets at fair value through profit or loss		10,106	-
Acquisition of property, plant and equipment		(3,195)	(1,731)
Acquisition of intangible assets		(221)	(196)
Increase (decrease) in other financial assets		6,209	(67,337)
Decrease in other non-current assets		754	723
Net cash generated by (used in) investing activities		7,227	(40,960)
Cash flows from financing activities:			
Decrease in guarantee deposits received		-	(50)
Repayment of lease principal		(2,762)	(2,645)
Cash dividends from capital surplus		-	(23,358)
Distribution of cash dividends		(69,209)	(19,898)
Cost of treasury shares repurchased		(10,334)	-
Net cash used in financing activities		(82,305)	(45,951)
Effect of exchange rate changes on cash and cash equivalents		881	688
Net increase in cash and cash equivalents		3,291	46,593
Cash and cash equivalents at beginning of period		99,053	52,460
Cash and cash equivalents at end of period	**$**	**102,344**	**99,053**

(The accompanying notes are an integral part of the parent company only financial statements.)
(Concluded)

Attachment 5:2025 Earnings Distribution Table

The 2025 earnings distribution proposal was resolved by the Board of Directors on March 9, 2026 as follows

GenMont Biotech Inc.

2025 Earnings Distribution Table

(In New Taiwan Dollars)

Item	Amount	
	Subtotal	Total
Retained earnings, beginning balance		3,242,843
Add: Net profit after tax for 2025	57,197,465	
Add: Adjustments to retained earnings for 2025 (Note 2)	688,378	
Less: Decrease in retained earnings from retirement of treasury shares (Note 3)	(3,353,835)	
Retained earnings, ending balance		57,774,851
Less: Legal reserve appropriated (10%)	(5,453,201)	
Add: Reversal of special reserve	0	
Earnings available for distribution		52,321,650
Distribution items		
Cash dividends to shareholders (NT$0.60 per share)	(51,606,219)	
Total distribution items		(51,606,219)
Undistributed retained earnings after distribution		715,431

Note:

1. Cash distributed from capital surplus is proposed at NT$0.20 per share, totaling NT$17,202,073.
2. Actuarial gains (losses) under defined benefit plans amounted to NT$688,378.
3. Retained earnings were reduced by NT$3,353,835, as the capital surplus arising from treasury share transactions of the same type was insufficient to cover the retirement of treasury shares.
4. Distribution amounts are rounded down to the nearest dollar. Any fractional amount less than NT$1 shall be recognized as other income of the Company.

Chairman: Chen Ken-te Manager: Chen Yu Chin Accounting Manager: Huang Chao Tang

Attachment 6:Comparison Table of Amendments to Rules of Procedure for Shareholders Meetings

GenMont Biotech Inc.

Comparison Table of Amendments to Rules of Procedure for Shareholders Meetings

Amended Article	Current Article	Explanation
Article 2: (Convening of shareholders' meetings and meeting notices) Unless otherwise provided by applicable laws and regulations, shareholders' meetings of the Company shall be convened by the Board of Directors. The Company shall, at least thirty (30) days prior to a regular shareholders' meeting or fifteen (15) days prior to a special shareholders' meeting, upload to the Market Observation Post System electronic files of the meeting notice, proxy forms, and the subject matters together with explanatory materials for each agenda item, including matters for ratification, discussion, and the election or dismissal of directors. In addition, electronic files of the shareholders' meeting handbook and supplementary materials shall be uploaded to the Market Observation Post System at least thirty (30) days prior to a regular shareholders' meeting or fifteen (15) days prior to a special shareholders' meeting. At least fifteen (15) days prior to the shareholders' meeting, the shareholders' meeting handbook and supplementary materials shall be prepared and made available for shareholders' review at all times. They shall be made available at the Company and its shareholder services agent and distributed at the meeting venue. The notice and public announcement shall specify the reasons for convening the meeting. With the consent of the recipient, the notice may be given in electronic form. The election or dismissal of directors; amendments to the Articles of Incorporation; capital reduction; application for cessation of public	Article 2: (Convening of shareholders' meetings and meeting notices) Unless otherwise provided by applicable laws and regulations, shareholders' meetings of the Company shall be convened by the Board of Directors. The Company shall, at least thirty (30) days prior to a regular shareholders' meeting or fifteen (15) days prior to a special shareholders' meeting, upload to the Market Observation Post System electronic files of the meeting notice, proxy forms, and the subject matters together with explanatory materials for each agenda item, including matters for ratification, discussion, and the election or dismissal of directors. In addition, electronic files of the shareholders' meeting handbook and supplementary materials shall be uploaded to the Market Observation Post System at least twenty-one (21) days prior to a regular shareholders' meeting or fifteen (15) days prior to a special shareholders' meeting. At least fifteen (15) days prior to the shareholders' meeting, the shareholders' meeting handbook and supplementary materials shall be prepared and made available for shareholders' review at all times. They shall be made available at the Company and its shareholder services agent and distributed at the meeting venue. The notice and public announcement shall specify the reasons for convening the meeting. With the consent of the recipient, the notice may be given in electronic form. The election or dismissal of directors; amendments to the Articles of Incorporation; capital reduction; application for cessation of public	Amended in accordance with the Order No. Jin-Guan-Zheng-Jiao-1140385797 issued by the Financial Supervisory Commission

Amended Article	Current Article	Explanation
offering; approval for directors to engage in competing business; capitalization of earnings or capital reserves; dissolution, merger, or demerger of the Company; or any matters set forth in the subparagraphs of Paragraph 1, Article 185 of the Company Act shall be listed in the notice of the reasons for convening the shareholders' meeting, with the essential content explained. None of the foregoing matters may be raised by way of extemporary motion. The essential content may be posted on a website designated by the competent securities authority or the Company, and the website address shall be specified in the notice.	offering; approval for directors to engage in competing business; capitalization of earnings or capital reserves; dissolution, merger, or demerger of the Company; or any matters set forth in the subparagraphs of Paragraph 1, Article 185 of the Company Act shall be listed in the notice of the reasons for convening the shareholders' meeting, with the essential content explained. None of the foregoing matters may be raised by way of extemporary motion. The essential content may be posted on a website designated by the competent securities authority or the Company, and the website address shall be specified in the notice.	
Where the reasons for convening the shareholders' meeting include a general re-election of all directors and independent directors and specify the commencement date of their term of office, such commencement date shall not be altered at the same meeting by any extemporary motion or by any other means after the re-election has been completed.	Where the reasons for convening the shareholders' meeting include a general re-election of all directors and independent directors and specify the commencement date of their term of office, such commencement date shall not be altered at the same meeting by any extemporary motion or by any other means after the re-election has been completed.	
A shareholder holding one percent (1%) or more of the total number of issued shares may submit a proposal for discussion at the Company's regular shareholders' meeting. Each proposal shall be limited to one item. Any proposal containing more than one item shall not be included in the agenda. Notwithstanding the foregoing, where a shareholder proposal is intended to urge the Company to promote the public interest or to fulfill its social responsibilities, the Board of Directors may still include such proposal in the agenda. In addition, the Board of Directors may exclude a shareholder proposal from the agenda if it falls under any of the circumstances set forth in Paragraph 4, Article 172-1 of the Company Act.	A shareholder holding one percent (1%) or more of the total number of issued shares may submit a proposal for discussion at the Company's regular shareholders' meeting. Each proposal shall be limited to one item. Any proposal containing more than one item shall not be included in the agenda. Notwithstanding the foregoing, where a shareholder proposal is intended to urge the Company to promote the public interest or to fulfill its social responsibilities, the Board of Directors may still include such proposal in the agenda. In addition, the Board of Directors may exclude a shareholder proposal from the agenda if it falls under any of the circumstances set forth in Paragraph 4, Article 172-1 of the Company Act.	
Prior to the book closure date for a regular shareholders' meeting, the Company shall publicly announce the acceptance of shareholder proposals,	Prior to the book closure date for a regular shareholders' meeting, the Company shall publicly announce the acceptance of shareholder proposals,	

Amended Article	Current Article	Explanation
including the means of submission (written or electronic), the place of submission, and the submission period; provided that such period shall not be less than ten (10) days.	including the means of submission (written or electronic), the place of submission, and the submission period; provided that such period shall not be less than ten (10) days.	
Shareholder proposals shall be limited to 300 words. Any proposal exceeding 300 words shall not be included in the agenda. The proposing shareholder shall attend the regular shareholders' meeting in person or by proxy and participate in the discussion of the proposal.	Shareholder proposals shall be limited to 300 words. Any proposal exceeding 300 words shall not be included in the agenda. The proposing shareholder shall attend the regular shareholders' meeting in person or by proxy and participate in the discussion of the proposal.	
Prior to issuing the notice of the shareholders' meeting, the Company shall notify the proposing shareholders of the review results and shall include proposals that comply with the provisions of this Article in the meeting notice. For any proposal not included in the agenda, the Board of Directors shall explain the reasons at the shareholders' meeting.	Prior to issuing the notice of the shareholders' meeting, the Company shall notify the proposing shareholders of the review results and shall include proposals that comply with the provisions of this Article in the meeting notice. For any proposal not included in the agenda, the Board of Directors shall explain the reasons at the shareholders' meeting.	

Attachment 7:List of Director Candidates

Type of Candidate	Shareholder Account No. or ID No.	Name	Education and Selected Past Positions	Current Position	Has Served as an Independent Director for Three Consecutive Terms	Shareholding (Shares)
Director	888	Ken-Te Chen	Master's degree, Yuan Ze University Member, the Legislative Yuan (4th to 8th terms) Speaker, the 13th Taoyuan County Council Chairman, GenMont Biotech Inc.	Chairman, GenMont Biotech (China) Inc. Chairman, GenMont Biotech Inc.	N/A	2,362,823
Director	25968	Kuo-Chieh Huang	Master of Public Relations and Advertising, Shih Hsin University Director, GenMont Biotech Inc.	Director, GenMont Biotech (China) Inc. Director, GenMont Biotech Inc. CEO, YouJun Construction Engineering Co., Ltd.	N/A	7,728,000
Director	927	Te-Hui Yang	Master of Public Relations and Advertising, Shih Hsin University Director, GenMont Biotech Inc.	Director, GenMont Biotech (China) Inc. Director, GenMont Biotech Inc.	N/A	1,583,792
Director	A1042XXXXX	Chuan-Chen Cho	Master of Accounting, National Chengchi University Ph.D. in Accounting, Xiamen University CPA, ShineWing Taiwan Chairman, Kaohsiung CPA Association Director, GenMont Biotech Inc.	Senior Partner, ShineWing Taiwan Supervisor, GenMont Biotech (China) Inc. Director, GenMont Biotech Inc.	N/A	0
Director	T1003XXXXX	Hsiang-Chou Li	43rd Class, Republic of China Military Academy Graduate Institute of National Policy and Public Affairs, National Chung Hsing University Center for Strategic and International Studies, Georgetown University, United States Commander, Military Police Command Commander, Republic of China Army (ROCA) Director-General, National Security Bureau (NSB) Minister, Veterans Affairs Council (VAC) Ambassador to Denmark	Consultant, Taiwan Puritic Corp. Consultant, Gold Stone Development Co., Ltd.	N/A	0

Independent Director	H1212XXXXX	Shih-Kun Chen	Master of Public Relations and Advertising, Shih Hsin University Supervisor, Great Power Construction Co., Ltd. Chairman, Frontier Investment Co., Ltd. Supervisor, Koto Construction Co., Ltd. Director, GenMont Biotech Inc.	Supervisor, Great Power Construction Co., Ltd. Chairman, Frontier Investment Co., Ltd.	No	0
Independent Director	A2250XXXXX	Man-Yao Huang	Bachelor of Laws (Judicial Division), National Taiwan University Master's degree in Law, Soochow University Passed the National Senior Examination for Attorneys (2007) Managing Attorney, Candor Attorneys-At-Law Family and Civil Mediator, Taoyuan District Court Legal Consultant, Taoyuan City Police Department Member of State Compensation Review Committee, Army Headquarters, Ministry of National Defense	Managing Attorney, Candor Attorneys-At-Law	No	0
Independent Director	G1207XXXXX	Chih-Pin Kao	Ph.D. in Philosophy, Barrington University, Iowa, USA Advisory Committee Member, Research, Development and Evaluation Commission, Executive Yuan Former Member of the National Assembly Invited Lecturer, Civil Service Development Institute and Central Police University Independent Director, Audit Committee and Remuneration Committee member, GenMont Biotech Inc.	Independent Director, Audit Committee and Remuneration Committee member, GenMont Biotech Inc.	No	0

Independent Director	L1024XXXXX	Ching-Lung Lin	Master in Public Finance, National Chengchi University Ph.D. in Business Administration, Nova Southeastern University, USA Councilor, 6th and 7th Taipei City Council Director, Mega International Commercial Bank Co., Ltd. Tax Officer, National Taxation Bureau of Taipei Investment Review Committee member, National Development Fund, Executive Yuan Adjunct Associate Professor, National Taipei College of Business and Chinese Culture University Associate Professor and Head of the Department of Finance and Taxation, Takming College of Commerce Chairman, Business Management Consultant Association (Taiwan) Independent Director and Audit Committee member, GenMont Biotech Inc.	Principal, Ching-Long CPA Firm Chairman, Ching Long Business Enterprise Inc. Chairman, Kingston Business Co., Ltd. Chairman, Wan-Ke Business Co., Ltd. Independent Director and Audit Committee member, GenMont Biotech Inc.	No	0

Attachment 8:Concurrent Positions of Director Candidates

Title	Name	Concurrent Position in Other Company
Director	Ken-Te Chen	Chairman, GenMont Biotech (China) Inc.
Director	Kuo-Chieh Huang	Director, GenMont Biotech (China) Inc. CEO, YouJun Construction Engineering Co., Ltd.
Director	Te-Hui Yang	Director, GenMont Biotech (China) Inc.
Director	Chuan-Chen Cho	Senior Partner, ShineWing Taiwan Supervisor, GenMont Biotech (China) Inc.
Director	Hsiang-Chou Li	Consultant, Taiwan Puritic Corp. Consultant, Gold Stone Development Co., Ltd.
Independent Director	Shih-Kun Chen	Supervisor, Great Power Construction Co., Ltd. Chairman, Frontier Investment Co., Ltd.
Independent Director	Ching-Lung Lin	Principal, Ching-Long CPA Firm Chairman, Ching Long Business Enterprise Inc. Chairman, Kingston Business Co., Ltd. Chairman, Player Hostel Co., Ltd.

4. Appendix

Appendix 1:Article of Incorporation

GenMont Biotech Inc.
Article of Incorporation
Chapter 1 General Provisions

Article 1: The Company is duly incorporated under the name of "景岳生物科技股份有限公司"in Chinese and "GenMont Biotech Incorporation" in English according to the Company Act.

Article 2: The scope of business of the Company sha be as follows:

C802041 Drugs and Medicines Manufacturing
C199990 Manufacture of Other Food Products Not Elsewhere Classified
C201010 Feed Manufacturing
C802051 Chinese Medicine Manufacturing
C802060 Veterinary Drug Manufacturing
C802100 Cosmetics Manufacturing
F108011 Wholesale of Chinese Medicines
F108021 Wholesale of Drugs and Medicines
F108040 Wholesale of Cosmetics
F208011 Retail Sale of Chinese Medicine
F208021 Retail Sale of Drugs and Medicines
F208040 Retail Sale of Cosmetics
F401010 International Trade
IG01010 Biotechnology Services
Research, Develop, manufacture, and sell the following products:

1.Antiallergic Oral Solution
2. Antiallergic Oral Vaccine
3. Antiallergic Active Pharmaceutical Ingredients
4. Raw Material of Antiallergic Healthy Food
5. Bacteria, fermentation liquid or other substances and vegetable extracts cultured by lactic acid bacteria, subtilis, fungi, actinomycetes, etc.

Article 2-1: If the Company deems it is necessary to carry out its business, the Company may provide endorsement and guarantees and act as a guarantee in accordance with the Company's regulations of endorsement and guarantee.

Article 2-2: If the Company deems it is necessary to carry out its business, the total amount of the Company's reinvestment may exceed 40% of the total paid-in share capital without being restricted by the Article 13 of the Company Act.

Article 3: The Company shall have its head office in the Southern Taiwan Science Park and may set up branches and/or business offices at various locations domestically and overseas

whenever the Company deems it is necessary with the resolution of the Board and the approved by the Competent authority

Article 4: (Deleted)

Chapter 2 Shares

Article 5: The total capital amount of the Company is one point five billion New Taiwan Dollars (NT$1,500,000,000), which is divided into one hundred and fifty million (150,000,000) shares with a par value of ten New Taiwan Dollars (NT$10) each and will be issued in installments by the Board of Directors. An amount of five million (5,000,000) shares from the above total amount are reserved for the issuance of share subscription warrants, special shares under ancillary share subscription rights, or corporate bonds with warrants to specific creditors.

Article 5-1: The Company may transfer shares to employees with an average price lower than the actual buyback shares according to the resolution which may be adopted by a large majority of two thirds of the voting powers of the shareholders present at a shareholders' meeting who present a majority of the total number of issued shares.

Article 6: (Delete)

Article 7: The share certificates hereof shall be name-bearing certificates, duly signed by or affixed with seals by the Chairman and duly authenticated by the competent authority or the issuance registry institution accredited by the competent authority before issuance. For the shares to be issued by the Company, the issuing company may be exempted from printing any share certificate for the shares issued. The Company may print its issued shares at one time but shall register or entrust custody the issued shares with a centralized securities depositary enterprise. The Company’s share certificates shall be duly issued in accordance with the Company Act and relevant regulations.

Article 8: No registration of transfer of shares shall be made within thirty days (30) prior to a regular shareholders ' meeting, nor within fifteen days (15) prior to a convening date of a special meeting, nor within 5 days (5) prior to the target day on which dividend, bonus, or other benefits is scheduled to be paid by the Company.

After issuing shares to the public, no registration of transfer of shares shall be made within sixty days (60) prior to a regular shareholders' meeting, nor within thirty days (30) prior to a convening date of a special meeting, nor within5 days (5) prior to the target day on which dividend, bonus, or other benefits is scheduled to be paid by the Company.

Chapter 3 Shareholders Meetings

Article 9: Shareholders' meeting hereof is divided into the regular meeting and Special meeting. The Former shall be convened annually within six months from the closing of each fiscal year. The latter may be duly convened according to relevant laws whenever the Company deems necessary. of shareholders: to be held at least once every year.

Article 10: A shareholder may issue a proxy in the form printed by the Company to expressly stipulate the scope of authorized representative(s) to attend a shareholders meeting on his or her behalf. The use of proxy shall be complied with the Article 177 of the Company

Act and "Regulations Governing the Use of Proxies for Attendance at Shareholders Meetings of Public Companies".

Article 11: A shareholder of the Company shall have one vote for each share he or she holds except the provisions set out in Article 179 of the Company Act.

Article 12: Unless otherwise provided for in the Company Act, resolutions shall be adopted by a majority vote at a meeting which is attended by shareholders who represent a majority of the total issued shares.

Article 12-1: The Company shall require a prior resolution approved by the shareholders' meeting when the Company intends to cancel the issuance of public shares. The article hereby shall not be altered during the period of OTC market and the listed company.

Article 12-2: The shareholders' meeting can be held by means of visual communication network or other methods promulgated by the central competent authority.

Chapter 4 Directors

Article 13: The Company shall have nine directors to be elected at the shareholders meeting from among the individuals having capacity to make juridical acts, with the term of three years and may be re-elected. The total ratio of shares held by the entire board shall be in accordance with relative regulations of Securities competent authority after issuing the public shares. The Company may purchase liability insurance for Directors to protect them against potential liabilities arising for exercising their duties during the tenure.

The Board of Directors of a company shall have at least three Independent directors who shall be elected by the shareholders' meeting.

The Company adopt a candidates nomination system according to the Article192-1 of the Company Act for election of the directors of the Company, The Company shall announce in a public notice, the application means, the period for accepting the nomination of director candidates, and other relevant matters in accordance with the Company Act and Securities and Exchange Act. The elections of Independent Directors and non-independent Directors shall proceed as one election, but the number elected shall be calculated separately.

The Company's Directors shall be duly elected by means of cumulative voting. Each common share with voting right is entitled to the number of ballots which are equivalent to the numbers of Directors to be elected. The ballots may be used to vote for one candidate or may be divided to vote for several candidates. The candidates shall be elected as Directors if they win more ballots represented by voting rights of the overall numbers

Article 13-1: The duties of the Board of Directors are as follows:

1. Approval of annual budgets and review of financial statements, including the review and inspection of annual business plan.
2. Appoint and discharge of the certified accountant and lawyer.
3. Review and discussion of the proposal with regards to dian, sell, lease, pledge, mortgage or other ways for the business operation and assets.

4. Approval of the reinvestment and the resale of shares
5. Approval of application on financing, guarantee, acceptance and any other credit and debt to the financial institutions or third parties
6. Approval of acquisition, assignment, grant, lease and major technical cooperation contracts of expertise, patent, trademark, and copyright.
7. Transfer with endorsement, guarantee and acceptance in the name of the Company.
8. Approval of credit to others
9. Approval of major transaction between the Company and interested party (Including Affiliated Enterprises)
10. Other exclusive duties in accordance with the Company Act, the Securities and Exchange Act, and relevant laws.

Article 13-2: The Company shall establish the Audit Committee in accordance with the Article 14-4 of the Securities and Exchange Act. The Audit Committee shall constitute the Independent Directors and be in charge of enforcing the regulations of the Company Act, the Securities and Exchange Act, and relevant laws.

Article 14: The Directors shall constitute the Board of Directors and shall elect one Chairman of the Board from among themselves by a majority at a meeting attended by at least two-thirds of the Directors. The Chairman shall externally represent the Company. the Directors may elect one vice Chairman to assist the Chairman.

Article 14-1: Board meetings shall be held at least once a quarter. Unless otherwise provided for in the Company Act, resolutions of the Board of Directors shall be adopted by a majority of the directors at a meeting attended by a majority of the directors. A director who has a personal interest in the matter under discussion at a board meeting shall explain to the board meeting the essential contents of such personal interest. In case a director appoints another director to attend a meeting of the Board of Directors in his/her behalf, he/she shall, in each time, issue a written proxy and state therein the scope of authority with reference to the subjects to be discussed at the meeting. A director may accept the appointment to act as the proxy referred to in the preceding paragraph of one other director only. In calling a meeting of the Board of Directors, a notice shall be given to each director no later than seven (7) days prior to the scheduled meeting date. In calling a meeting of the Board of Directors, a notice shall set forth therein the subject(s) to be discussed at the meeting In the case of emergency, a meeting of the Board of Directors may be convened at any time.

The notice set forth in the preceding may adopted the means of written, facsimile, or electronic transmission.

Article 15: During the Chairman’s absence or unavailability for performance of duties for any reasons, the delegation shall be duly handled in accordance with Article 208 of the Company Act.

Article 16: The directors of the Company may receive remuneration such as traveling expenses and salaries. The remuneration is authorized to the Board of Directors to propose based on the extent of directors' participation in the business operations and the level of

directors' contributions, to the Company with reference to the industry standards.

Chapter 5 Managers

Article 17: Company may have one General Manager and a certain number of Vice General Managers and Managers who shall be duly appointed, discharged, and compensated in accordance with Article 29 of the Company Act.

Chapter 6 Accounting

Article 18: Upon closing of each fiscal year, the Board of Directors shall prepare the following documents and shall submit to the regular shareholders meeting for ratification:

1. Annual business report
2. The financial statements
3. The proposals of surplus earnings distribution or loss make-up

Article 19: (Delete)

Article 20: After closing of accounts, if there are earnings, the Company shall first pay the tax, make up the losses for the preceding years and then set aside 10% of the net profit as a legal capital reserve and special reserve in accordance with the relevant laws. With respect to any balance herein together with the undistributed cumulative profits from previous years and from the current year, the Company may allot dividends to shareholders on the basis of resolution of the shareholders meeting. The ratio for the dividend shall not exceed 50% of the total distribution.

If the Company has earnings, it shall set aside the following amount as remuneration to directors and employees. When there are accumulated losses, the Company shall offset the appropriate amounts before remuneration.

1. Directors' remuneration shall not exceed five percent.
2. Employees' remuneration ranges from 2% to 10%.

At least 50% of the amount allocated for employee remuneration in the preceding paragraph shall be designated for distribution to non-managerial employees.

Distribution of dividends and bonuses by cash shall be resolved at Board meeting, with over two-third of directors in attendance and approved by over half of the attending directors and reported to the shareholders' meeting.

Article 20-1: Distribution of statutory surplus reserves and capital reserves by cash shall be resolved at Board meeting, with over two-third of directors in attendance and approved by over half of the attending directors and reported to the shareholders' meeting.

Chapter 7 Bylaws

Article 21: Any matters not provided for herein shall be subject to the Company Act.

Article 22: These articles were duly enacted on November 22, 2000 and were duly amended on
December 18, 2000 as the 1st amendment;
April 29, 2001 as the 2nd amendment;
November 2, 2001 as the 3rd amendment;

April 22, 2002 as the 4th amendment;
July 29, 2002 as the 5th amendment;
May 26, 2003 as the 6th amendment;
May 17, 2004 as the 7th amendment;
June 30, 2006 as the 8th amendment;
August 28, 2006 as the 9th amendment;
May 30, 2007 as the 10th amendment;
April 3, 2008 as the 11th amendment;
July 23, 2008 as the 12th amendment;
June 23, 2009 as the 13th amendment;
August 9, 2010 as the 14th amendment;
June 26, 2012 as the 15th amendment;
June 24, 2013 as the 16th amendment;
December 31, 2013 as the 17th amendment;
April 30, 2014 as the 18th amendment;
June 30, 2015 as the 19th amendment;
June 28, 2016 as the 20th amendment;
June 27, 2018 as the 21th amendment;
June 28, 2019 as the 22th amendment;
June 30, 2020 as the 23th amendment;
May 27, 2022 as the 24th amendment.
May 28, 2025 as the 25th amendment.

Appendix 2:Rules of Procedure for Shareholders Meetings (Before Amendment)

GenMont Biotech Inc.
Rules of Procedure for Shareholders Meetings

Article 1: The rules of procedures for this Company's shareholders meetings, except as otherwise provided by law, regulation, or the articles of incorporation, shall be as provided in these Rules.

Article 2: (Convening of shareholders' meetings and meeting notices) Unless otherwise provided by applicable laws and regulations, shareholders' meetings of the Company shall be convened by the Board of Directors.

The Company shall, at least thirty (30) days prior to a regular shareholders' meeting or fifteen (15) days prior to a special shareholders' meeting, upload to the Market Observation Post System electronic files of the meeting notice, proxy forms, and the subject matters together with explanatory materials for each agenda item, including matters for ratification, discussion, and the election or dismissal of directors. In addition, electronic files of the shareholders' meeting handbook and supplementary materials shall be uploaded to the Market Observation Post System at least twenty-one (21) days prior to a regular shareholders' meeting or fifteen (15) days prior to a special shareholders' meeting. At least fifteen (15) days prior to the shareholders' meeting, the shareholders' meeting handbook and supplementary materials shall be prepared and made available for shareholders' review at all times. They shall be made available at the Company and its shareholder services agent and distributed at the meeting venue.

The notice and public announcement shall specify the reasons for convening the meeting. With the consent of the recipient, the notice may be given in electronic form.

The election or dismissal of directors; amendments to the Articles of Incorporation; capital reduction; application for cessation of public offering; approval for directors to engage in competing business; capitalization of earnings or capital reserves; dissolution, merger, or demerger of the Company; or any matters set forth in the subparagraphs of Paragraph 1, Article 185 of the Company Act shall be listed in the notice of the reasons for convening the shareholders' meeting, with the essential content explained. None of the foregoing matters may be raised by way of extemporary motion. The essential content may be posted on a website designated by the competent securities authority or the Company, and the website address shall be specified in the notice.

Where the reasons for convening the shareholders' meeting include a general re-election of all directors and independent directors and specify the commencement date of their term of office, such commencement date shall not be altered at the same meeting by any extemporary motion or by any other means after the re-election has been completed.

A shareholder holding one percent (1%) or more of the total number of issued shares may submit a proposal for discussion at the Company's regular shareholders' meeting. Each proposal shall be limited to one item. Any proposal containing more than one item shall not be included in the agenda. Notwithstanding the foregoing, where a shareholder proposal is intended to urge the Company to promote the public interest or to fulfill its social responsibilities, the Board of Directors may still include such proposal in the agenda. In addition, the Board of Directors may exclude a shareholder proposal from the agenda if it falls under any of the circumstances set forth in Paragraph 4, Article 172-1 of the Company Act.

Prior to the book closure date for a regular shareholders' meeting, the Company shall publicly announce the acceptance of shareholder proposals, including the means of submission (written or electronic), the place of submission, and the submission period; provided that such period shall not be less than ten (10) days.

Shareholder proposals shall be limited to 300 words. Any proposal exceeding 300 words shall not be included in the agenda. The proposing shareholder shall attend the regular shareholders' meeting in person or by proxy and participate in the discussion of the proposal.

Prior to issuing the notice of the shareholders' meeting, the Company shall notify the proposing shareholders of the review results and shall include proposals that comply with the provisions of this Article in the meeting notice. For any proposal not included in the agenda, the Board of Directors shall explain the reasons at the shareholders' meeting.

Article 3: For each shareholders meeting, a shareholder may appoint a proxy to attend the meeting by providing the proxy form issued by this Corporation and stating the scope of the proxy's authorization.

A shareholder may issue only one proxy form and appoint only one proxy for any given shareholders meeting, and shall deliver the proxy form to this Corporation before five days before the date of the shareholders meeting. When duplicate proxy forms are delivered, the one received earliest shall prevail unless a declaration is made to cancel the previous proxy appointment.

After a proxy form has been delivered to this Corporation, if the shareholder intends to attend the meeting in person or to exercise voting rights by correspondence or electronically, a written notice of proxy cancellation shall be submitted to this Corporation before two business days before the meeting date. If the cancellation notice is submitted after that time, votes cast at the meeting by the proxy shall prevail.

Article 4: (Principles determining the time and place of a shareholders meeting)
The venue for a shareholders meeting shall be the premises of this Corporation, or a place easily accessible to shareholders and suitable for a shareholders meeting. The meeting may begin no earlier than 9 a.m. and no later than 3 p.m. Full consideration shall be given to the opinions of the independent directors with respect to the place and time of the meeting.

Article 5: (Preparation of attendance book and related documents)
The Company shall prepare an attendance book for attending shareholders or their proxies (collectively, "shareholders") to sign in, or attending shareholders may submit a sign-in card in lieu of signing in.
The Company shall provide attending shareholders with the shareholders' meeting handbook, annual report, attendance card, speaker's slips, voting ballots, and other meeting materials. Where directors are to be elected, ballots for such election shall also be provided.
Shareholders shall attend the shareholders' meeting by presenting an attendance card, sign-in card, or other proof of attendance. Proxy solicitors shall also present identification documents for verification.
Where a shareholder is a government entity or a juristic person, it may be represented by more than one representative at a shareholders' meeting. Where a juristic person is appointed as a proxy to attend a shareholders' meeting, it may designate only one person to act as its representative at the meeting.

Article 6: (The chair and non-voting participants of a shareholders meeting)
If a shareholders meeting is convened by the Board of Directors, the meeting shall be chaired by the chairperson of the board. When the chairperson of the board is on leave or for any reason unable to exercise the powers of the chairperson, the vice chairperson shall act in place of the chairperson; if there is no vice chairperson or the vice chairperson also is on leave or for any reason unable to exercise the powers of the vice chairperson, the chairperson shall appoint one of the managing directors to act as chair, or, if there are no managing directors, one of the directors shall be appointed to act as chair. Where the chairperson does not make such a designation, the managing directors or the directors shall select from among themselves one person to serve as chair.
It is advisable that shareholders meetings convened by the Board of Directors be attended by a majority of the directors.
If a shareholders meeting is convened by a party with power to convene but other than the Board of Directors, the convening party shall chair the meeting. When there are two or more such convening parties, they shall mutually select a chair from among themselves.
This Corporation may appoint its attorneys, certified public accountants, or related persons retained by it to attend the shareholders meeting in a non-voting capacity.

Article 7: (Documentation of a shareholders meeting by audio or video)
This Corporation shall make an audio or video recording of the proceedings of the shareholders meeting.
The recorded materials of the preceding paragraph shall be retained for at least one year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recording shall be retained until the conclusion of the litigation.

Article 8: Attendance at shareholders meetings shall be calculated based on numbers of shares.
The number of shares in attendance shall be calculated according to the shares indicated by the attendance book and sign-in cards handed in plus the number of shares whose voting rights are exercised by correspondence or electronically.
The chair shall call the meeting to order at the appointed meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement, provided that no more than two such postponements, for a combined total of no more than one hour, may be made. If the quorum is not met after two postponements and the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned.
If the quorum is not met after two postponements as referred to in the preceding paragraph, but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Article 175, paragraph 1 of the Company Act; all shareholders shall be notified of the tentative resolution and another shareholders meeting shall be convened within one month. But for the resolution required supermajority vote shall abide by the Company Act.
When, prior to conclusion of the meeting, the attending shareholders represent a majority of the total number of issued shares, the chair may resubmit the tentative resolution for a vote by the shareholders meeting pursuant to Article 174 of the Company Act.

Article 9: (Discussion of proposals)
Where a shareholders' meeting is convened by the Board of Directors, the agenda shall be determined by the Board of Directors. All proposals (including extemporary motions and amendments to the original proposals) shall be voted on separately. The meeting shall proceed in accordance with the agenda as scheduled, which shall not be changed without a resolution of the shareholders' meeting.
Where a shareholders' meeting is convened by a person with convening authority other than the Board of Directors, the provisions of the preceding paragraph shall apply mutatis mutandis.

Before the agenda set forth in the preceding two paragraphs (including extemporary motions) has been duly concluded, the chair shall not adjourn the meeting without a resolution of the shareholders' meeting. Where the chair adjourns the meeting in violation of these Rules, the remaining members of the Board of Directors shall promptly assist the attending shareholders in electing a new chair in accordance with applicable laws and regulations, by a majority of the voting rights represented at the meeting, and shall continue the meeting.

The chair shall provide sufficient opportunity for explanation and discussion of proposals, as well as amendments or extemporary motions proposed by shareholders. When the chair considers that a proposal has been sufficiently discussed, the chair may declare the discussion closed, put the matter to a vote, and allow adequate time for voting.

Article 10: (Shareholders speech)

Before speaking, an attending shareholder must specify on a speaker's slip the subject of the speech, his/her shareholder account number (or attendance card number), and account name. The order in which shareholders speak will be set by the chair.

A shareholder in attendance who has submitted a speaker's slip but does not actually speak shall be deemed to have not spoken. When the content of the speech does not correspond to the subject given on the speaker's slip, the spoken content shall prevail.

Except with the consent of the chair, a shareholder may not speak more than twice on the same proposal, and a single speech may not exceed 5 minutes. If the shareholder's speech violates the rules or exceeds the scope of the agenda item, the chair may terminate the speech.

When an attending shareholder is speaking, other shareholders may not speak or interrupt unless they have sought and obtained the consent of the chair and the shareholder that has the floor; the chair shall stop any violation.

When a juristic person shareholder appoints two or more representatives to attend a shareholders meeting, only one of the representatives so appointed may speak on the same proposal.

After an attending shareholder has spoken, the chair may respond in person or direct relevant personnel to respond.

Article 11: (Calculation of voting shares and recusal system)

Voting at a shareholders meeting shall be calculated based the number of shares.

With respect to resolutions of shareholders meetings, the number of shares held by a shareholder with no voting rights shall not be calculated as part of the total number of issued shares.

When a shareholder is an interested party in relation to an agenda item, and there is the likelihood that such a relationship would prejudice the interests of this Corporation, that shareholder may not vote on that item, and may not exercise voting rights as proxy for any other shareholder.

The number of shares for which voting rights may not be exercised under the preceding paragraph shall not be calculated as part of the voting rights represented by attending shareholders.

With the exception of a trust enterprise or a shareholder services agent approved by the competent securities authority, when one person is concurrently appointed as proxy by two or more shareholders, the voting rights represented by that proxy may not exceed three percent of the voting rights represented by the total number of issued shares. If that percentage is exceeded, the voting rights in excess of that percentage shall not be included in the calculation.

Article 12: A shareholder shall be entitled to one vote for each share held, except where the shares are restricted or are deemed non-voting shares under Paragraph 2, Article 179 of the Company Act.

When the Company convenes a shareholders' meeting, it shall adopt electronic means for the exercise of voting rights and may also allow voting rights to be exercised in writing. Where voting rights are exercised in writing or by electronic means, the method of exercise shall be specified in the notice of the shareholders' meeting. A shareholder who exercises voting rights in writing or by electronic means shall be deemed to have attended the meeting in person; provided, however, that such shareholder shall be deemed to have abstained from voting on any extemporary motions and any amendments to the original proposals. Accordingly, the Company should avoid submitting extemporary motions or amendments to original proposals.

A shareholder intending to exercise voting rights in writing or by electronic means shall deliver a declaration of intent to the Company no later than two (2) days prior to the date of the shareholders' meeting. Where duplicate declarations are delivered, the one received earliest shall prevail, except where a declaration is made to revoke a prior declaration. After a shareholder has exercised voting rights in writing or by electronic means, if the shareholder intends to attend the shareholders' meeting in person, the shareholder shall revoke the prior declaration of intent by the same means by which the voting rights were exercised no later than two (2) days prior to the date of the shareholders' meeting. If the revocation is made after the prescribed time, the voting rights exercised in writing or by electronic means shall prevail. Where a shareholder has exercised voting rights both in writing or by electronic means and by appointing a proxy to attend the meeting, the voting rights exercised by the proxy at the meeting shall prevail.

Unless otherwise provided by the Company Act or the Company's Articles of Incorporation, a proposal shall be adopted upon approval by a majority of the voting rights represented by the attending shareholders. At the time of voting, the chair or a person designated by the chair shall announce, on a proposal-by-proposal basis,

the total number of voting rights represented by the attending shareholders. If, upon inquiry by the chair, no objection is raised by the attending shareholders, the proposal shall be deemed adopted, with the same effect as a resolution passed by voting. Where any objection is raised, the proposal shall be put to a vote in accordance with the preceding paragraph.

Where there is an amendment or an alternative proposal to a proposal, the chair shall present the original proposal together with the amendment or alternative and determine the order in which they are to be put to a vote. If any one of the proposals is adopted, the others shall be deemed rejected, and no further voting shall be required.

The chair shall appoint persons to monitor and count the votes; provided that the vote-monitoring personnel shall be shareholders of the Company.

The counting of votes shall be conducted publicly at the venue of the shareholders' meeting. The results of the voting shall be announced on-site and recorded.

Article 13: (Elections)

Where directors are to be elected at a shareholders' meeting, the election shall be conducted in accordance with the relevant election rules adopted by the Company, and the results shall be announced on-site immediately.

The ballots for the election referred to in the preceding paragraph shall be sealed and signed by the vote-monitoring personnel and kept in proper custody for at least one (1) year. Where a shareholder institutes an action pursuant to Article 189 of the Company Act, the ballots shall be retained until the conclusion of such action.

Article 14: Resolutions of a shareholders' meeting shall be recorded in the minutes. The minutes shall be signed or affixed with the seal of the chair and distributed to all shareholders within twenty (20) days after the conclusion of the meeting. The preparation and distribution of the minutes may be made in electronic form.

For a company whose shares are publicly issued, the distribution of the minutes may be effected by way of public announcement.

The minutes shall accurately record the year, month, day, and place of the meeting, the name of the chair, the method of adopting resolutions, a summary of the proceedings, and the results of voting (including the number of voting rights). Where directors or independent directors are elected, the number of voting rights received by each candidate shall be disclosed. The minutes shall be retained for the duration of the Company's existence.

For the method of adopting resolutions referred to in the preceding paragraph, where a resolution is deemed adopted after the chair has inquired of all attending shareholders and no objection is raised, the minutes shall state: "Resolved, without objection, after inquiry by the chair of all attending shareholders." Where there is any objection, the minutes shall specify that the resolution was put to a vote and shall record the number and proportion of voting rights in favor of the resolution.

Article 15: (Public disclosure)

On the day of a shareholders meeting, this Corporation shall compile in the prescribed format a statistical statement of the number of shares obtained by solicitors through solicitation and the number of shares represented by proxies, and shall make an express disclosure of the same at the place of the shareholders meeting.

If matters put to a resolution at a shareholders meeting constitute material information under applicable laws or regulations or under Taiwan Stock Exchange Corporation (or GreTai Securities Market) regulations, this Corporation shall upload the content of such resolution to the MOPS within the prescribed time period.

Article 16: (Maintaining order at the meeting place)

Staff handling administrative affairs of a shareholders meeting shall wear identification cards or arm bands.

The chair may direct the proctors or security personnel to help maintain order at the meeting place. When proctors or security personnel help maintain order at the meeting place, they shall wear an identification card or armband bearing the word "Proctor."

At the place of a shareholders meeting, if a shareholder attempts to speak through any device other than the public address equipment set up by this Corporation, the chair may prevent the shareholder from so doing.

When a shareholder violates the rules of procedure and defies the chair's correction, obstructing the proceedings and refusing to heed calls to stop, the chair may direct the proctors or security personnel to escort the shareholder from the meeting.

Article 17: (Recess and resumption of a shareholders meeting)

When a meeting is in progress, the chair may announce a break based on time considerations. If a force majeure event occurs, the chair may rule the meeting temporarily suspended and announce a time when, in view of the circumstances, the meeting will be resumed.

If the meeting venue is no longer available for continued use and not all of the items (including extraordinary motions) on the meeting agenda have been addressed, the shareholders meeting may adopt a resolution to resume the meeting at another venue.

A resolution may be adopted at a shareholders meeting to defer or resume the meeting within five days in accordance with Article 182 of the Company Act.

Article 18: These Rules shall take effect after having been submitted to and approved by a shareholders meeting. Subsequent amendments thereto shall take effect in the same manner.

Appendix 3: Rules for Director Elections

GenMont Biotech Inc.
Rules for Director Elections

Article 1 The Rules are adopted pursuant to the Company Act and the Articles of Incorporation of the Company. Elections of directors shall be conducted in accordance with the Rules.

Article 2 The overall composition of the Board of Directors shall be taken into consideration in the selection of this Corporation's directors. Each board member shall have the necessary knowledge, skill, and experience to perform their duties

Article 3 The members of the Company's Audit Committee shall constitute at least one accounting or finance specialist.

Article 4 The qualifications and election for the independent directors of this Corporation shall comply with the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies.

Article 5 Elections of directors shall be conducted in accordance with the candidate nomination system and procedures set out in Article 192-1 of the Company Act.

Article 6 The cumulative voting method shall be used for election of the directors in accordance with the Company Act. Each share will have voting rights in number equal to the directors to be elected, and may be cast for a single candidate or split among multiple candidates. The candidate who wins the most ballots representing the voting rights shall be elected as the director.

Article 7 The Board of Directors shall prepare separate ballots for directors in numbers corresponding to the directors or supervisors to be elected. The number of voting rights associated with each ballot shall be specified on the ballots, which shall then be distributed to the attending shareholders at the shareholders meeting. Attendance card numbers printed on the ballots may be used instead of recording the names of voting shareholders.

Article 8 Elections of directors shall be conducted the candidate nomination system in accordance with the Articles of Incorporation of the Company. The Company shall elect directors at the shareholders meeting from among the individuals having capacity to make juridical acts. The number of directors will be as specified in this Company's Articles of Incorporation, with voting rights separately calculated for independent and non-independent director positions. Those receiving ballots representing the highest numbers of voting rights will be elected sequentially according to their respective numbers of votes. When two or more persons receive the same number of votes, thus exceeding the specified number of positions, they shall draw lots to determine the winner, with the chair drawing lots on behalf of any person not in attendance.

If the elected directors waive their right before applying for alteration registration to the competent authority, the vacant seat shall be filled by the candidates with second most votes.

More than one-half of the elected directors of the Company shall not be mutually related in any of the following ways:

1. Spouses.
2. Relatives within the second degree of kinship.
3. The collateral Relatives within the second degree of kinship.
4. Representatives of the same juristic person.

Article 9 Before the election begins, the chair shall appoint a number of persons with shareholder status to perform the respective duties of vote monitoring and counting personnel. The ballot boxes shall be prepared by the Board of Directors and publicly checked by the vote monitoring personnel before voting commences.

Article 10 If a candidate is a shareholder, a voter must enter the candidate's account name and shareholder account number in the "candidate" column of the ballot; for a non-shareholder, the voter shall enter the candidate's full name and identity card number. However, when the candidate is a governmental organization or juristic-person shareholder, the name of the governmental organization or juristic-person shareholder shall be entered in the column for the candidate's account name in the ballot paper, or both the name of the governmental organization or juristic-person shareholder and the name of its representative may be entered. When there are multiple representatives, the names of each respective representative shall be entered.

Article 11 A ballot is invalid under any of the following circumstances:

1. The ballot was not prepared by the Board of Directors.
2. A blank ballot is placed in the ballot box.
3. The writing is unclear, indecipherable, or has been altered, which is not corrected according to the law upon request.

4. The candidate whose name is entered in the ballot is a shareholder, but the candidate's account name and shareholder account number do not conform with those given in the shareholder register, or the candidate whose name is entered in the ballot is a non-shareholder, and a cross-check shows that the candidate's name and identity card number do not match.
5. Two or more candidates are listed in the same column on the same ballot paper.
6. Other words or marks are entered in addition to the candidate's account name or shareholder account number (or identity card number) and the number of voting rights allotted.
7. The name of the candidate entered in the ballot is identical to that of another shareholder, but no shareholder account number or identity card number is provided in the ballot to identify such individual.

Article 12 The voting rights shall be calculated on site immediately after the end of the poll, and the results of the calculation shall be announced by the chair on the site.

Article 13 The Board of Directors shall issue notifications to the persons elected as directors.

Article 14 The Rules and any amendments hereto, shall be implemented after approval by a shareholders meeting.

Article 15 Bylaws:

The Rules were duly enacted on November 2, 2001 and were duly amended on

April 22, 2002 as the 1st amendment;

June 30, 2006 as the 2nd amendment;

May 30, 2007 as the 3rd amendment;

July 23, 2008 as the 4th amendment;

June 26, 2012 as the 5th amendment;

June 30, 2020 as the 6th amendment.

Appendix 4: Current Shareholding of Directors

Shareholding of Directors

1. The ratio and number of shares of the Company's current directors and supervisors are as follows:
   The number of issued common shares 86,010,364
   The minimum shareholding requirement of all directors 6,880,829

2. As the record shown in the shareholder register as of the book closure date (April 10, 2026), the number of shares held by all directors is as follows:

Title	Name	Elected date	Number of Shares	Ratio (%)
Chairman	Chen Ken-te	2023/6/30	2,362,823	2.75%
Director	Huang Kuo Chieh	2023/6/30	6,158,000	7.16%
Director	Yang Te-hui	2023/6/30	1,583,792	1.84%
Director	Sean Lin	2023/6/30	10,000	0.01%
Director	Jackson Jwo	2023/6/30	0	0.00%
Independent Director	Huang Tse-jen	2023/6/30	0	0.00%
Independent Director	Lu Jyh-Feng	2023/6/30	0	0.00%
Independent Director	Kao, Chih-bin	2023/6/30	0	0.00%
Independent Director	Lin Ching Long	2023/6/30	0	0.00%
Numbers and ratio of shares held by all directors			10,114,615	11.76%

Note: The tenure is from June 30, 2023 to June 29, 2026.

Appendix 5: The shareholder proposal

The proposal screening results at the shareholders meeting.

Description:

1. According to Article 172-1 of the Company Act,"Shareholder(s) holding one percent (1%) or more of the total number of outstanding shares of a company may propose to the Company a proposal in writing for discussion at a regular shareholders' meeting, provided that only one matter shall be allowed in each single proposal; The number of words of a proposal to be submitted by a shareholder shall be limited to not more than three hundred (300) words"
2. The time period of submission for the shareholder' s proposal was from March 31, 2026 to April 10, 2026 and was announced on the MOPS.
3. The Company didn't receive any shareholder's proposal.